Please assess the completion status of the following clinical trial:

Trial Title: A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Enrolled in the Canadian avelumab1LM Patient support program (PSP)~* Histologically confirmed diagnosis of stage IV LA/mUC~* No evidence of disease progression following first-line platinum-based chemotherapy~* Receipt of avelumab1LM following 1L platinum-based chemotherapy~* Received the last dose of chemotherapy no more than 10 weeks before entering the PSP~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~* ≥6 months of follow-up from initiation of AVE 1LM therapy until study end date, unless the patient has died, with known date of death.~Exclusion Criteria:~* Diagnosed with LA/mUC and enrolled in the PSP, but did not receive avelumab~* Pregnancy at index date~* Participation in an interventional clinical trial at any point during the study period~The index date will be considered as the initiation of index therapy. The index therapy will be considered as the avelumab 1LM treatment after 1L platinum-based chemotherapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Canadian Patients with Advanced Urothelial Carcinoma (Type: None): Patients with LA/mUC who following 4-6 cycles of platinum chemotherapy and have not progressed, received avelumab, recommended dose of 10mg/kg body weight intravenously administered over 60 minutes every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).